The 2016 Faculty Scholars
... Mitochondria, cells’ tiny power plants, are essential for many cellular activities, and their dysfunction is associated with aging, metabolic disorders, Parkinson’s disease, bacterial infections, and cancer. Cole Haynes is investigating the mechanisms cells use to monitor their mitochondria and, whe ...
... Mitochondria, cells’ tiny power plants, are essential for many cellular activities, and their dysfunction is associated with aging, metabolic disorders, Parkinson’s disease, bacterial infections, and cancer. Cole Haynes is investigating the mechanisms cells use to monitor their mitochondria and, whe ...
Immunomodulatory Effects of Human Immunodeficiency
... suppress new responses in a cell-cell contact dependent manner. The ability of the HIV-1 primed T cells to proliferate was severely impaired and this condition was reversed after a combined blockade of PD-1, CTLA-4 and TRAIL. Furthermore, more inhibitory molecules TIM-3, LAG-3, CD160, BLIMP-1, and F ...
... suppress new responses in a cell-cell contact dependent manner. The ability of the HIV-1 primed T cells to proliferate was severely impaired and this condition was reversed after a combined blockade of PD-1, CTLA-4 and TRAIL. Furthermore, more inhibitory molecules TIM-3, LAG-3, CD160, BLIMP-1, and F ...
Treg and CTLA-4: Two intertwining pathways to
... that cells with immunoregulatory activity could be identified on the basis of their CD45 isoform usage [36], or their expression of CD38 [37] or CD25 [38e41]. It is now well established that Treg are essential for the maintenance of tolerance to self-tissues (particularly those that announce their pr ...
... that cells with immunoregulatory activity could be identified on the basis of their CD45 isoform usage [36], or their expression of CD38 [37] or CD25 [38e41]. It is now well established that Treg are essential for the maintenance of tolerance to self-tissues (particularly those that announce their pr ...
Immunogenicity - Biologics and Biosimilars
... 1. Sekhon BS, Saluja V. Biosimilars: an overview. Dovepress J. 2011;1(1):1-11. 2. Bendtzen KII. Front Immunol. 2015;6(109):1-5. 3. FDA: Guidelines for industry. Immunogenicity assessment for therapeutic protein ...
... 1. Sekhon BS, Saluja V. Biosimilars: an overview. Dovepress J. 2011;1(1):1-11. 2. Bendtzen KII. Front Immunol. 2015;6(109):1-5. 3. FDA: Guidelines for industry. Immunogenicity assessment for therapeutic protein ...
determining the innate and adaptive immune responses to vesicular
... The goal of this research project is to determine the response of dendritic cells and T cells to vesicular stomatitis virus (VSV) vectors that express flagellin. VSV is currently in clinical trials as a recombinant vaccine vector against heterologous antigens (1). Incorporating flagellin gene into t ...
... The goal of this research project is to determine the response of dendritic cells and T cells to vesicular stomatitis virus (VSV) vectors that express flagellin. VSV is currently in clinical trials as a recombinant vaccine vector against heterologous antigens (1). Incorporating flagellin gene into t ...
study of the anti – pregnancy
... produced by plasma cells because there is an interaction between the lymphocyte B antigen-sensitive and the presence of the antigens (Abbas et al., 2000; Tizard, 2004). The processes could be resumed in brief as follows: PAG protein entered into the body of laboratory animals and was processed in th ...
... produced by plasma cells because there is an interaction between the lymphocyte B antigen-sensitive and the presence of the antigens (Abbas et al., 2000; Tizard, 2004). The processes could be resumed in brief as follows: PAG protein entered into the body of laboratory animals and was processed in th ...
Pyroptosis: A Caspase-1-Dependent Programmed Cell Death and a
... type I and autophagic cell death, or type II) or passive (necrosis or type III). Pyroptosis is categorized as programmed cell death, as it requires metabolic energy and is mediated by specific cellular pathways, namely, the inflammasome and caspase-1. Pyroptotic cells display a distinct set of morph ...
... type I and autophagic cell death, or type II) or passive (necrosis or type III). Pyroptosis is categorized as programmed cell death, as it requires metabolic energy and is mediated by specific cellular pathways, namely, the inflammasome and caspase-1. Pyroptotic cells display a distinct set of morph ...
... A comprehension of the genetics of host resistance to malaria is essential to understanding the complexity of the host immune response and its interaction with the parasite infection. Current research is directed towards dissection of host genetic factors involved in both the host immune response an ...
Vitiligo-Like Hypopigmentation Induced by Imiquimod Case Report Zekayi Kutlubay,
... In our patients despite discontinuation of imiquimod and utilization of a herbal cream, the hypopigmentation did not improve. Previous case reports also mentioned that the hypopigmented areas remained unchanged despite discontinuation of imiquimod and suggested that trial with macrolide immunomodula ...
... In our patients despite discontinuation of imiquimod and utilization of a herbal cream, the hypopigmentation did not improve. Previous case reports also mentioned that the hypopigmented areas remained unchanged despite discontinuation of imiquimod and suggested that trial with macrolide immunomodula ...
webinar 3
... • Studies show that probiotic bacteria can stimulate and regulate the immune response in the body. • This immune supporting action of probiotics is thought to explain the results of trials demonstrating that probiotic supplementation in infants and children may reduce the symptoms of immune based at ...
... • Studies show that probiotic bacteria can stimulate and regulate the immune response in the body. • This immune supporting action of probiotics is thought to explain the results of trials demonstrating that probiotic supplementation in infants and children may reduce the symptoms of immune based at ...
Disruption of Dendritic Cell Instruction Virus and Its Avirulent Vaccine
... Virulent varicella-zoster virus (VZV) can spread in immunocompetent humans, resulting in symptoms mostly of the skin. In contrast, vaccine Oka (V-Oka), the attenuated VZV vaccine strain, only rarely causes clinical reactions. The mechanisms underlying these pathogenetic differences are unclear. In t ...
... Virulent varicella-zoster virus (VZV) can spread in immunocompetent humans, resulting in symptoms mostly of the skin. In contrast, vaccine Oka (V-Oka), the attenuated VZV vaccine strain, only rarely causes clinical reactions. The mechanisms underlying these pathogenetic differences are unclear. In t ...
Transferrin and the Transferrin Receptor: Of Magic Bullets
... acids. Each monomer possesses a short cytoplasmic Nterminus region, a single transmembranar domain and a large glycosylated extracellular region. The extracellular domain is involved in ligand binding. Each monomer can bind to one molecule of Trf. The intracellular segment contains a site for recept ...
... acids. Each monomer possesses a short cytoplasmic Nterminus region, a single transmembranar domain and a large glycosylated extracellular region. The extracellular domain is involved in ligand binding. Each monomer can bind to one molecule of Trf. The intracellular segment contains a site for recept ...
Multiple Trypanosoma cruzi antigens containing tandemly repeated
... Uppsala, Sweden. Abbreviation: H2, human Chagasic serum. ...
... Uppsala, Sweden. Abbreviation: H2, human Chagasic serum. ...
Epitope Masking in a Murine Model Independently from Red Cell
... fetal red cells. Much of our information on how anti-D may prevent immunization to D+ RBCs has come from seminal studies dating back to the 1960s on human male D2 volunteers immunized with D+ RBCs. In many of these studies and others that have followed, it was noticed that the dose of anti-D that ca ...
... fetal red cells. Much of our information on how anti-D may prevent immunization to D+ RBCs has come from seminal studies dating back to the 1960s on human male D2 volunteers immunized with D+ RBCs. In many of these studies and others that have followed, it was noticed that the dose of anti-D that ca ...
Ginkgo biloba extract EGb 761 has anti
... disease (4,5). Here, we show that EGb 761 has anti-inflammatory properties in vitro and can be used to prevent and treat colitis in vivo. Mechanistically, we show that this is at least in part due to the ability of EGb 761 to drive CD4þ effector T cell apoptosis. Materials and methods Chemicals and ...
... disease (4,5). Here, we show that EGb 761 has anti-inflammatory properties in vitro and can be used to prevent and treat colitis in vivo. Mechanistically, we show that this is at least in part due to the ability of EGb 761 to drive CD4þ effector T cell apoptosis. Materials and methods Chemicals and ...
Enrichment of IFN-γ producing cells in different murine adipose
... GTPases and inducible nitric oxide synthase28. In the infected WT mice a 14-, 26-, 17- and 2-fold increase was respectively observed in immunity-related GTPase family M member 1 (Irgm1), interferon gamma induced GTPase (Igtp), guanylate binding protein 2 (Gbp2) and nitric oxide synthase 2, inducible ...
... GTPases and inducible nitric oxide synthase28. In the infected WT mice a 14-, 26-, 17- and 2-fold increase was respectively observed in immunity-related GTPase family M member 1 (Irgm1), interferon gamma induced GTPase (Igtp), guanylate binding protein 2 (Gbp2) and nitric oxide synthase 2, inducible ...
Photochemotherapy induces the apoptosis of - HAL
... Hannani et al. cultured T-cells, whereas in human they are usually PBMC. Therefore, the immunomodulation and effectors identified in these studies could be different than those involved in human ECP. Among the treated cells, monocytes are a major group since they represent up to 30% of PBMC(12). It ...
... Hannani et al. cultured T-cells, whereas in human they are usually PBMC. Therefore, the immunomodulation and effectors identified in these studies could be different than those involved in human ECP. Among the treated cells, monocytes are a major group since they represent up to 30% of PBMC(12). It ...
Predicting pathogen-specific CD8 T cell immune responses
... been modified by reverse genetics to express the NP68 epitope that is recognized by the F5 T cell receptor (TCR). Hence, we can use transgenic naive CD8 T cells expressing the F5 TCR to monitor the response induced by these 3 different pathogens (H1N1-NP, VV-NP and Lm-NP). Although these pathogens a ...
... been modified by reverse genetics to express the NP68 epitope that is recognized by the F5 T cell receptor (TCR). Hence, we can use transgenic naive CD8 T cells expressing the F5 TCR to monitor the response induced by these 3 different pathogens (H1N1-NP, VV-NP and Lm-NP). Although these pathogens a ...
Radioimmunotherapy Is More Effective than Antifungal Treatment
... RIT efficacy [7], which is obviously absent in vitro. It has been demonstrated that mice mount an intense antibody response to fungal melanin that includes antibodies of immunoglobulin M and immunoglobulin G isotypes, which points to the stimulation of the immune system by melanin [12]. Given that a ...
... RIT efficacy [7], which is obviously absent in vitro. It has been demonstrated that mice mount an intense antibody response to fungal melanin that includes antibodies of immunoglobulin M and immunoglobulin G isotypes, which points to the stimulation of the immune system by melanin [12]. Given that a ...
Induction of protective immunity to Cryptococcal infection in mice by
... pathogen and the resolution of the fungal infection (7–9). It is well established that cell-mediated immunity (CMI) plays a critical role in anticryptococcal defense, as is evident from the higher prevalence of cryptococcal infections in immunocompromised patients (1). This is recapitulated in anima ...
... pathogen and the resolution of the fungal infection (7–9). It is well established that cell-mediated immunity (CMI) plays a critical role in anticryptococcal defense, as is evident from the higher prevalence of cryptococcal infections in immunocompromised patients (1). This is recapitulated in anima ...
Intravaginal Zinc Oxide Tetrapod Nanoparticles as Novel
... Published April 27, 2016, doi:10.4049/jimmunol.1502373 The Journal of Immunology ...
... Published April 27, 2016, doi:10.4049/jimmunol.1502373 The Journal of Immunology ...
Discoveries in Diabetes Spring 2016
... root. He also wants to treat people with earlyonset and long-term diabetes to stop the disease from causing deeper damage. The Fife lab now is working on developing several biomarkers for tracking down the antigen that triggers the immune system to attack itself. It’s complicated work that mirrors t ...
... root. He also wants to treat people with earlyonset and long-term diabetes to stop the disease from causing deeper damage. The Fife lab now is working on developing several biomarkers for tracking down the antigen that triggers the immune system to attack itself. It’s complicated work that mirrors t ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.